- Home
- HQI vs ATOS Comparison
HQI vs ATOS Comparison
Compare HQI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HQI | ATOS |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.0M | 83.3M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HQI | ATOS |
|---|---|---|
| Price | $10.85 | $0.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.00 | $6.33 |
| AVG Volume (30 Days) | 47.1K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 412.84 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $31,691,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $0.55 |
| 52 Week High | $15.75 | $1.29 |
Technical Indicators
Market Signals| Indicator | HQI | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 41.32 |
| Support Level | $10.33 | $0.57 |
| Resistance Level | $11.47 | $0.67 |
| Average True Range (ATR) | 0.61 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 50.76 | 46.34 |
Price Performance
Historical ComparisonAbout HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.